UK +44 (0)1223 491486      USA toll free 1-866 877 2185

Search
Generic filters
30 03, 2022

Endoderm implants

By |2022-03-31T15:39:06+00:00March 30th, 2022|organoid news, stem cells|Comments Off on Endoderm implants

Implantable endoderm organoids combine synthetic support structures and cells to repair or replace the function of endoderm-derived organs like the pancreas, liver, colon, stomach, intestines, lungs, and gall bladder. Adult cells are notoriously difficult to expand in vitro without loss of function, so many implants have harnessed new technologies based on induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). Pioneers in the field are working to optimize cell lines and effectively scale manufacture protocols to transition to the clinic and fulfill the promise of these next generation of stem cell therapies.

8 02, 2022

pep talk February 2022

By |2022-02-24T12:06:24+00:00February 8th, 2022|news, newsletter, resources, stem cells|Comments Off on pep talk February 2022

On Friday, 11th February, it’s International Day of Women and Girls in Science 2022. To celebrate, I’d like to give a big shout-out to people of all genders who champion gender equality in science and inspire the next generations of scientists, thank you!

10 01, 2022

pep talk January 2022

By |2022-02-24T12:06:46+00:00January 10th, 2022|news, newsletter, resources, stem cells|Comments Off on pep talk January 2022

Happy New Year! It’s five years since Marko and I founded Qkine, the time has flown. Highlights have been the wonderful feedback we’ve had from customers and launching innovative products such as the first true animal-free TGFβ1, tag-free thermostable FGF2-G3, and demonstrating the efficacy of HGF NK1 in hepatocyte differentiation.

10 01, 2022

the 5th anniversary of Qkine

By |2022-01-10T09:30:43+00:00January 10th, 2022|cellular agriculture, news, protein science, resources, stem cells|Comments Off on the 5th anniversary of Qkine

There has been an impressive drive towards innovation in stem cell protocols this year. As 2021 comes to a close, we reflect on the highlights for stem cell science over the year. It was great to see new culture media, such as B8 and “Beefy-9”, published, developments in cultivated meat science hit the news and iPSC-based therapies edge closer to the clinic. Reproducibility remains the underlying theme, and indeed requirement, for maximising the impact of these wonderful developments and at Qkine we’ll continue to do everything we can to help in 2022.

3 12, 2021

pep talk December 2021

By |2022-02-24T12:09:56+00:00December 3rd, 2021|news, newsletter, resources, stem cells|Comments Off on pep talk December 2021

There has been an impressive drive towards innovation in stem cell protocols this year. As 2021 comes to a close, we reflect on the highlights for stem cell science over the year. It was great to see new culture media, such as B8 and “Beefy-9”, published, developments in cultivated meat science hit the news and iPSC-based therapies edge closer to the clinic. Reproducibility remains the underlying theme, and indeed requirement, for maximising the impact of these wonderful developments and at Qkine we’ll continue to do everything we can to help in 2022.

1 10, 2021

pep talk October 2021

By |2022-02-24T12:10:21+00:00October 1st, 2021|news, newsletter, resources, stem cells|Comments Off on pep talk October 2021

October update celebrating the launch of hyperstable FGF2-G3 for media optimisation, new media recipe quick reference resources for organoid researchers and the launch of animal-free OSM, which completes the hepatocyte differentiation growth factor set. Not forgetting us becoming an ISO9001: 2015 certified manufacturer!

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, news, press release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

Title

Go to Top